On May 21, Kelun-Biotech Biopharmaceutical rose 3.52% in regular trading, trading at 454.6 HKD/share, with trading volume of approximately 51.11 million HKD. The rally was driven by continued catalysts from multiple clinical milestones.

On the news front, Merck announced that sac-TMT (sacituzumab tirumotecan), a TROP2 antibody-drug conjugate licensed from Kelun-Biotech, successfully met both overall survival (OS) and progression-free survival (PFS) co-primary endpoints in the global Phase III TroFuse-005 trial. The study enrolled 776 patients with advanced or recurrent endometrial cancer who had progressed after platinum-based chemotherapy and anti-PD-(L)1 immunotherapy. Sac-TMT demonstrated statistically significant and clinically meaningful improvements versus investigator-choice chemotherapy, with the key secondary endpoint of objective response rate also achieving positive results. This marks the first and only Phase III ADC trial to demonstrate dual OS and PFS improvement in this indication, positioning sac-TMT as a potential backbone therapy. Additionally, the companys PD-1×VEGF bispecific antibody SKB118 received IND approval from Chinas NMPA for advanced solid tumors, further reinforcing pipeline momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)